New vaccine safety check for infants: PREVENAR 20 under Real-World scrutiny

NCT ID NCT06622109

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study monitors the safety of the PREVENAR 20 vaccine in 1,100 infants aged 2 to 6 months in Japan. Infants receive four doses as part of routine care, and researchers track any side effects. The goal is to ensure the vaccine is safe for widespread use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20)
What this could lead to: If successful, this study will confirm that PREVENAR 20 is safe for infants, supporting its routine use to prevent pneumococcal disease.
What could go wrong: This is an observational safety study, not a test of effectiveness. Side effects may still occur, and results may not apply outside Japan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL DISEASE

Contacts and locations

Locations

Pfizer

Tokyo, 151-8589, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.